Launched on 6 October 2026Last updated on

INR targets and warfarin management

Gives the indication for a vitamin K antagonist and the target INR for each indication, ESC beside ACC/AHA: mechanical aortic and mitral valves by prosthesis thrombogenicity and patient risk factors (ESC 2021 table), the On-X lower target, the first 3 months after a bioprosthesis or repair, valvular AF with moderate–severe mitral stenosis, antiphospholipid syndrome (venous, arterial, recurrent), Fontan circulation, DVT/PE and LV thrombus, with the cases where a DOAC is contraindicated. With the current INR it says what to do: below range (dose increase, causes, heparin bridging for mechanical valves), above range (omit doses, oral vitamin K, PCC and IV vitamin K for major bleeding, when to restart), and before a procedure (continue for minor procedures, stop 5 days before surgery, bridging and restart).

Upload a report, lab sheet or echo picture to fill this calculator automatically.
1. Indication for a VKA
2. Mechanical valve
ESC 2021 table: prosthesis thrombogenicity × patient risk factors
3. Current INR
Enter the latest result to get what to do now
Bleeding
Range used for the current INR
4. Planned procedure
How long to stop warfarin, and bridging
Target INR · Mechanical aortic valve
2.5
Range 2.0–3.0 (ESC)
Enter the current INR for what to do now
Decision guide
Target INR
ESC
  • Target INR 2.5 (2.0–3.0)
    I
    No patient risk factor
ACC/AHA
  • Target INR 2.5 (2.0–3.0)
    I
    Bileaflet or current-generation tilting-disc valve, no risk factor
Indication for a VKA
  • Lifelong VKA for every mechanical valve
    IESC 2021 · ACC/AHA 2020
    Warfarin (or acenocoumarol, phenprocoumon). INR self-monitoring in trained patients; aim for a time in therapeutic range ≥ 70%.
  • Do not use a DOAC with a mechanical valve
    IIIESC 2021 · ACC/AHA 2020
    Dabigatran (RE-ALIGN) and apixaban (PROACT Xa) caused more valve thrombosis and bleeding than warfarin.
INR targets at a glance
IndicationESCACC/AHA
Mechanical aortic, low thrombogenicity, no risk factor2.52.5
Mechanical aortic with a risk factor3.0 (low) · 3.5 (medium) · 4.0 (high)3.0
Mechanical mitral / tricuspid3.0 (low) · 3.5 (medium) · 4.0 (high)3.0
On-X aortic after 3 months, no risk factor2.51.5–2.0 + aspirin (IIb)
Bioprosthesis / repair, first 3 months2.5 (mitral, tricuspid)2.5 for 3–6 months
Valvular AF (moderate–severe MS)2.0–3.02.0–3.0
APS venous · arterial2.0–3.0 · 2.0–3.0 + aspirin or 3.0–4.0EULAR 2019
Fontan, DVT/PE, LV thrombus2.0–3.02.0–3.0

ESC patient risk factors: mitral or tricuspid replacement, previous thromboembolism, AF, mitral stenosis of any degree, LVEF < 35%. Range = target ± 0.5.

Print / Save PDF: opens the print dialog with a table of the inputs and result; choose Save as PDF to keep a file. Made on this device only; nothing is uploaded.
References
  1. Vahanian A, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561-632.
  2. Otto CM, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease. Circulation 2021;143:e72-e227.
  3. Praz F, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2025.
  4. Van Gelder IC, et al. 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2024;45:3314-3414.
  5. Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation. Circulation 2024;149:e1-e156.
  6. Connolly SJ, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation (INVICTUS). N Engl J Med 2022;387:978-988.
  7. Puskas J, et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the PROACT trial. J Thorac Cardiovasc Surg 2014;147:1202-1211.
  8. Tektonidou MG, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019;78:1296-1304.
  9. Baumgartner H, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021;42:563-645.
  10. Rychik J, et al. Evaluation and management of the child and adult with Fontan circulation: a scientific statement from the AHA. Circulation 2019;140:e234-e284.
  11. Holbrook A, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed (ACCP). Chest 2012;141:e152S-e184S.
  12. Keeling D, et al. Guidelines on oral anticoagulation with warfarin – fourth edition (BSH). Br J Haematol 2011;154:311-324.
  13. Tomaselli GF, et al. 2020 ACC Expert Consensus Decision Pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol 2020;76:594-622.
  14. Douketis JD, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest 2022;162:e207-e243.
  15. Halvorsen S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J 2022;43:3826-3924.
  16. Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:3720-3826.
  17. Konstantinides SV, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J 2020;41:543-603.